Previous 10 | Next 10 |
home / stock / grts / grts articles
NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ:GRTS)....
NEW YORK, July 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds invest...
NEW YORK, July 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritsto...
NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Gritstone bio, Inc. ("Gritstone" or the "...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ:GRTS)....
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds invest...
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritsto...
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds invest...
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritsto...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...